These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15544137)

  • 1. [Documented advantages of Lantus in comparison with NPH].
    Birgersson MO
    Lakartidningen; 2004 Oct; 101(42):3270, 3273; author reply 3273. PubMed ID: 15544137
    [No Abstract]   [Full Text] [Related]  

  • 2. [Documented advantages of insulin Lantus when compared with NPH insulin].
    Frid A
    Lakartidningen; 2004 Sep; 101(39):3014. PubMed ID: 15493644
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination therapy in NIDDM.
    Raskin P
    N Engl J Med; 1992 Nov; 327(20):1453-4. PubMed ID: 1406863
    [No Abstract]   [Full Text] [Related]  

  • 4. Addition of insulin to oral therapy in type 2 diabetes.
    Dağdelen S
    N Engl J Med; 2008 Mar; 358(11):1197; author reply 1198. PubMed ID: 18337612
    [No Abstract]   [Full Text] [Related]  

  • 5. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.
    Al Shamsi AM
    Pediatrics; 2008 Sep; 122(3):675-6; author reply 676. PubMed ID: 18762540
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale for using combinations of short-acting insulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus.
    Bolli GB
    J Pediatr Endocrinol Metab; 1999; 12 Suppl 3():737-44. PubMed ID: 10626264
    [No Abstract]   [Full Text] [Related]  

  • 8. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New methods in insulin treatment].
    Neuwirth G
    Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The journey to metabolic control in diabetes: many more miles to go.
    Silverstein JH; Rosenbloom AL
    J Pediatr; 2003 Dec; 143(6):704-6. PubMed ID: 14657811
    [No Abstract]   [Full Text] [Related]  

  • 12. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are you up to date on diabetes medications?
    Kestel F
    Am J Nurs; 1994 Jul; 94(7):48-52. PubMed ID: 8017497
    [No Abstract]   [Full Text] [Related]  

  • 14. [When diet and oral antidiabetics are no longer enough. Optimal management of the diabetic patient with insulin].
    Rosak C
    MMW Fortschr Med; 2002 May; 144(18):28-30, 32, 34. PubMed ID: 12422704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin].
    Krankenpfl J; 2004; 42(5-6):172. PubMed ID: 15527234
    [No Abstract]   [Full Text] [Related]  

  • 17. Premixed biphasic insulin analogs - a choice for pediatric patients with type 2 diabetes rather than type 1 diabetes?
    Danne T
    Pediatr Diabetes; 2006 Feb; 7(1):1-3. PubMed ID: 16489967
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotted dermopathy in a diabetic patient due to insulin allergy.
    Maheshwari M; Goyal D; Desouza P; Goyal RK
    J Assoc Physicians India; 2004 Nov; 52():926-7. PubMed ID: 15906848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Koenen C
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):E1. PubMed ID: 18806804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.